Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04697069 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform Rash
A Phase 2 study, sponsored by Vanda Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT04697069 is a Phase 2 study that was terminated before completion, run by Vanda Pharmaceuticals. The registered enrollment target is 4 participants.
The verdict
NCT04697069, a Phase 2 study, was terminated before completion, sponsored by Vanda Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
Efficacy and Safety of imsidolimab in participants with epidermal growth factor receptor inhibitor (EGFRi)/mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase inhibitor (MEKi)-associated acneiform Rash
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Imsidolimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2021-05-04 |
| Est. Completion | 2021-12-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04697069
The ClinicalTrials.gov registry entry for NCT04697069 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04697069 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04697069 about?
NCT04697069 is a clinical study titled "A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform Rash". Efficacy and Safety of imsidolimab in participants with epidermal growth factor receptor inhibitor (EGFRi)/mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase inhibitor (MEKi)-associated acneiform Rash
What is the current status of trial NCT04697069?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2021-05-04. Estimated completion is 2021-12-13.
What interventions are being tested in trial NCT04697069?
The interventions under investigation include: Placebo (BIOLOGICAL), Imsidolimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04697069?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.